A Multi-center, Randomized Open-label, Single-dose, Parallel Group Investigation of the Relative Bioavailability, Tolerability and Dose-exposure Relationship of a High Concentration Liquid Formulation (HCLF) Versus a Lyophilized Formulation (LyoF) of RO4909832 (Gantenerumab) When Administered by su
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2016
At a glance
- Drugs Gantenerumab (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Roche
- 15 Aug 2012 Actual initiation date (May 2012) added as reported by ClinicalTrials.gov.
- 17 Jul 2012 New trial record
- 01 May 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.